Safety of rilpivirine and boceprevir coadministration in HIV-infected patients treated for acute hepatitis C virus infection

AIDS. 2016 Jan 28;30(3):529-30. doi: 10.1097/QAD.0000000000000950.

Authors

Sebastiaan J Hullegie¹, Brenda C M de Winter, Dirk Posthouwer, Peter P Koopmans, Mark A A Claassen, David M Burger, Bart J A Rijnders

Affiliation

¹ aDepartment of Internal Medicine and Infectious DiseasesbDepartment of Hospital Pharmacy, Erasmus Medical Center, RotterdamcDepartment of Internal Medicine and Medical Microbiology, Maastricht University Medical Center, MaastrichtdDepartment of Internal Medicine and Infectious DiseaseseDepartment of Pharmacy, Radboud University Medical Center, Nijmegen, the Netherlands.

PMID: 26558734
DOI: 10.1097/QAD.0000000000000950

No abstract available

Publication types

Letter

MeSH terms

Adult
Antiviral Agents / adverse effects*
Antiviral Agents / pharmacokinetics
Drug Interactions*
HIV Infections / complications*
Hepatitis C / drug therapy*
Humans
Male
Netherlands
Plasma / chemistry
Proline / adverse effects
Proline / analogs & derivatives*
Proline / pharmacokinetics
Rilpivirine / adverse effects*
Rilpivirine / pharmacokinetics

Substances

Antiviral Agents
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
Proline
Rilpivirine